On November 19, Block Inc. held its first Investor Day in three years. Jack Dorsey, the company’s cofounder, chief executive, and “Block Head,” took to the stage and summarily posed what many ...

Explosives manufacturer Dyno Nobel has valued its Phosphate Hill mine and fertiliser plant at zero ahead of a 10-month period in which it has vowed to sell or shut the struggling but strategically ...

Dyno Nobel trimmed its loss as underlying profit and dividends rose, with explosives now its sole focus after the fertilisers divestment. Dyno Nobel reported a statutory net loss of $53.2 million ...

If you remember the fun of the Windsible 1:64-scale wind tunnel for Hot Wheels-sized cars, you might also like the new Runsible dynamometer that puts those cars into action, even letting them spin ...

According to Chevrolet, the new Corvette ZR1’s twin-turbo 5.5-liter flat-plane crank V8 delivers 1,064 hp and 828 lb-ft of torque. That’s enough to blast it to 60 mph (96 km/h) in 2.3 seconds and down ...

Crews responded to a fire on Tuesday morning at Dyno Nobel in Biwabik Township, which supplies industrial explosives and blasting services used by the mining industry. The call came in around 10:45 ...

Please provide your email address to receive an email when new articles are posted on . Results showed high to very high relative reliability among patients. Interrater reliability had wider value ...

SAN FRANCISCO—Kicking off J.P. Morgan week, Dyno Therapeutics announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological ...

In his book The Mathematical Universe, mathematician William Dunham wrote of John Venn’s namesake legacy, the Venn diagram, “No one in the long history of mathematics ever became better known for less ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...

Roche will apply Dyno Therapeutics’ engineered adeno-associated virus (AAV) capsid platform to develop next-generation AAV vectors for gene therapies targeting unspecified neurological diseases, ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality ...